Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 15 Products per page

Toca 511/FC
Read More
Toca 511 (vocimagene amiretrorepvec) and Toca FC (5-fluorocytosine) are under investigation as a
combination therapy for use in recurrent high-grade gliomas, including GBM. Toca 511 is an
injectable retroviral replicating vector that encodes the prodrug activator enzyme cytosine deaminase
(CD), which is derived from yeast and not found in the human genome
April 13, 2016
Find out more
Japan Pricing and Reimbursement

$2,995.00

Pricing and reimbursement processes are closely connected in Japan, with drug pricing largely dependent on innovation. However, achieving premium pricing is difficult, thereby limiting sales potential.
November 4, 2016
Find out more
2014 October Dermatology Survey

$599.00

We performed a 5-question survey of 21 dermatologists to gauge usage of drugs and devices for the treatment of common dermatological conditions and for aesthetic procedures.
October 30, 2014
Find out more
Market Spotlight: Insomnia

$1,318.00

This Market Spotlight report covers the insomnia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming events and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
June 23, 2022
Find out more
Siponimod
Read More
Siponimod (Novartis) is a sphingosine-1-phosphate (S1P) agonist with selectivity for the S1P1 and S1P5 receptor subtypes.
November 24, 2017
Find out more
Market Spotlight: Lysosomal Storage Disorders

$1,318.00

This Market Spotlight report covers the Lysosomal Storage Disorders market, comprising epidemiology, key marketed and pipeline drugs, recent events and analyst opinion, key regulatory events, licensing and asset deals, probability of success, and clinical trials.
April 28, 2022
Find out more
Viibryd
Read More
Viibryd (vilazodone; Allergan) belongs to a new class of antidepressants, combining selective serotonin reuptake inhibitor activity with partial 5-HT1A receptor agonism, in order to produce its therapeutic effect.
March 29, 2019
Find out more
Pulse Oximetry Devices Market

$3,000.00

This report provides an overview of pulse oximetry, and profiles selected leading products and technologies. The report also provides a market and competitive analysis of the global pulse oximetry devices market, including five-year market forecast and share by supplier.
December 22, 2017
Find out more
Advair
Read More
Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose combination of an inhaled corticosteroid (fluticasone propionate) and a long-acting beta 2 agonist (salmeterol). The drug has anti-inflammatory and bronchodilatory effects on patients with asthma.
July 31, 2018
Find out more
U.S. Benign Uterine Conditions Therapy Systems Market

$3,750.00

This report presents an overview of the most common types of treatment for the benign uterine conditions of menorrhagia and uterine fibroids/polyps; among these therapies are dilation and curettage, hysterectomy, hysteroscopy, and myomectomy. Market and competitive analyses for the medical devices used in these treatments also are presented.

May 1, 2013
Find out more
Avonex
Read More
Avonex is a biological therapy derived from the interferon family, and Biogen’s leading drug for treating relapsing-remitting multiple sclerosis (RRMS).
November 24, 2017
Find out more
Contract Research Organizations: Health and Wealth in 2013

$5,000.00

For public contract research organizations (CROs), the financial story in 2013 was one of solid and steady growth. Revenues grew and company-estimated forecasts for 2014 are also positive.
November 3, 2016
Find out more
Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)

$1,318.00

This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals, a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
May 26, 2022
Find out more
blisibimod
Read More
Blisibimod is a selective antagonist of B-cell activating factor (BAFF)/B lymphocyte stimulator (BLyS) that is in Phase III development for SLE. Elevated levels of BAFF have also been associated with several B-cell-mediated autoimmune diseases including…
April 5, 2016
Find out more
Respiratory Care: Mechanical Ventilators and Pulmonary Function Testing Systems

$4,750.00

Asthma and COPD affect an estimated 590 million people worldwide, with an additional 114 million affected by COVID-19 from March 2020 to March 2021. Devices used in the diagnosis and treatment of these and other respiratory disorders include mechanical ventilators and pulmonary function testing systems.
March 30, 2021
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *